SARCLISA® (isatuximab-irfc) Injection for IV use | 500 mg/25mL, 100 mg/5mL.

IKEMA: SARCLISA + Kd

Explore SARCLISA + Kd

mPFS: Not yet reached (NR) with SARCLISA + Kd (n=179) vs 20.27 months with Kd alone (n=123), HR=0.548 (95% CI: 0.37, 0.82; P=0.0032)1

ICARIA-MM: SARCLISA + Pd

Explore SARCLISA + Pd

mPFS: 11.53 months with SARCLISA + Pd (n=154)
vs 6.47 months with Pd alone (n=153), HR=0.596
(95% CI: 0.44, 0.81; P=0.0010)1

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend isatuximab-irfc (SARCLISA) for previously treated multiple myeloma2

  • In combination with pomalidomide and dexamethasone (Preferred, Category 1)
  • In combination with carfilzomib and dexamethasone

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

mPFS=median progression-free survival; NCCN=National Comprehensive Cancer Network; PFS=progression-free survival.

References: 1. SARCLISA [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.7.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed May 5, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.